Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
-
Pilsen, Czech Republic, October 6, 2020 - AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, today...
-
First of its kind clinical study combining a Natural Killer (NK) cell product with an innate cell engager (ICE®)Study investigates NK cells preloaded with AFM13, followed by subsequent weekly...
-
Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
-
Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
-
Continued progress in the AFM13 pTCL REDIRECT monotherapy studyAFM24 is recruiting patients in cohort 2 of a Phase 1/2a clinical trial Genentech’s RO7297089 is actively recruiting patients into a...
-
Heidelberg, Germany, August 5, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
-
Heidelberg, Germany, August 4, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today...
-
Heidelberg, Germany, July 10, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that...
-
AFM24: Affimed successfully completed the first dose cohort of its first-in-human phase 1/2A Study; Cohort 2 is open for patient recruitment Data on Affimed’s AFM24 (EGFR/CD16A) and...